

Ensitrelvir for COVID-19: real-time meta analysis of 3 studies

@CovidAnalysis, April 2024, Version 9

<https://c19early.org/enmeta.html>

Abstract

Statistically significant lower risk is seen for viral clearance. 3 studies from 2 independent teams (all from the same country) show statistically significant improvements.

Meta analysis using the most serious outcome reported shows 26% [-14-52%] lower risk, without reaching statistical significance. Results are worse for peer-reviewed studies. Currently all studies are RCTs.

Currently there is limited data, with only 1 control event for the most serious outcome in trials to date. Studies to date are from only 2 different groups.

No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments are more effective.

All data to reproduce this paper and sources are in the appendix.

Ensitrelvir for COVID-19


Improvement, Studies, Patients

All studies	26%	3	1,450
Hospitalization	-1%	1	1,195
Recovery	10%	2	1,376
Viral clearance	38%	3	1,417
RCTs	26%	3	1,450
Peer-reviewed	9%	2	1,422
Early	26%	3	1,450

c19early.org

April 2024

Relative Risk




100% Evolution of COVID-19 clinical evidence

Effective

c19early.org

April 2024



HIGHLIGHTS

Ensitrelvir reduces risk for COVID-19 with very high confidence for viral clearance and very low confidence for recovery and in pooled analysis.

Real-time updates and corrections, transparent analysis with all results in the same format, consistent protocol for 69 treatments, outcome specific analyses and combined evidence from all studies.

3 ensitrelvir COVID-19 studies

c19early.org
April 2024

	Improvement, RR [CI]			Treatment	Control
Mukae (DB RCT)	45%	0.55 [0.37-0.81]	viral load	14 (n)	14 (n)
Mukae (DB RCT)	9%	0.91 [0.76-1.08]	improv.	116 (n)	111 (n)
Yotsuyan.. (DB RCT)	-1%	1.01 [0.06-16.1]	hosp.	1/595	1/600


Early treatment 26% 0.74 [0.48-1.14] 1/725 1/725

Tau² = 0.08, I² = 63.0%, p = 0.17

All studies 26% 0.74 [0.48-1.14] 1/725 1/725

Tau² = 0.08, I² = 63.0%, p = 0.17

Effect extraction pre-specified
(most serious outcome, see appendix)



Timeline of COVID-19 ensitrelvir studies (pooled effects)

c19early.org
April 2024




Figure 1. A. Random effects meta-analysis. This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix. **B. Timeline of results in ensitrelvir studies.** The marked date indicates the time when efficacy was known with a statistically significant improvement of $\geq 10\%$ from ≥ 3 studies for one or more specific outcome.

Introduction

Immediate treatment recommended. SARS-CoV-2 infection primarily begins in the upper respiratory tract and may progress to the lower respiratory tract, other tissues, and the nervous and cardiovascular systems, which may lead to cytokine storm, pneumonia, ARDS, neurological issues ^{Duloquin, Hampshire, Scardua-Silva, Yang}, cardiovascular complications ^{Eberhardt}, organ failure, and death. Minimizing replication as early as possible is recommended.

Many treatments are expected to modulate infection. SARS-CoV-2 infection and replication involves the complex interplay of 50+ host and viral proteins and other factors ^{Note A, Malone, Murigneux, Lv, Lui, Niarakis}, providing many therapeutic targets for which many existing compounds have known activity. Scientists have predicted that over 7,000 compounds may reduce COVID-19 risk ^{c19early.org}, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications.

Supporting research. *In Vitro* studies demonstrate efficacy in VeroE6/TMPRSS2 ^{Note B, Kuroda}, HEK293T/ACE2-TMPRSS2 ^{Note C, Kuroda}, and MucilAir ^{Note D, Kuroda} cells. Animal studies demonstrate efficacy in BALB/c mice ^{Note E, Nobori, Kuroda} and Syrian hamsters ^{Note F, Kuroda}. Preclinical studies demonstrate efficacy for the ancestral ^{Note G, Kuroda}, delta ^{Note H, Kuroda}, and omicron ^{Note I, Kuroda} variants.

Analysis. We analyze all significant controlled studies of ensitrelvir for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random effects meta-analysis results for all studies, individual outcomes, peer-reviewed studies, and Randomized Controlled Trials (RCTs).

Treatment timing. Figure 2 shows stages of possible treatment for COVID-19. Prophylaxis refers to regularly taking medication before becoming sick, in order to prevent or minimize infection. Early Treatment refers to treatment immediately or soon after symptoms appear, while Late Treatment refers to more delayed treatment. Currently all ensitrelvir studies use early treatment.




Figure 2. Treatment stages.

Preclinical Research

In Vitro studies demonstrate efficacy in VeroE6/TMPRSS2 ^{Note B, Kuroda}, HEK293T/ACE2-TMPRSS2 ^{Note C, Kuroda}, and MucilAir ^{Note D, Kuroda} cells. Animal studies demonstrate efficacy in BALB/c mice ^{Note E, Nobori, Kuroda} and Syrian hamsters ^{Note F, Kuroda}. Preclinical studies demonstrate efficacy for the ancestral ^{Note G, Kuroda}, delta ^{Note H, Kuroda}, and omicron ^{Note I, Kuroda} variants.

An *In Vitro* study supports the efficacy of ensitrelvir ^{Kuroda}.

2 *In Vivo* animal studies support the efficacy of ensitrelvir ^{Kuroda, Nobori}.

Preclinical research is an important part of the development of treatments, however results may be very different in clinical trials. Preclinical results are not used in this paper.

Results

Table 1 summarizes the results for all studies, for Randomized Controlled Trials, for peer-reviewed studies, and for specific outcomes. Figure 3, 4, 5, 6, and 7 show forest plots for random effects meta-analysis of all studies with pooled effects, hospitalization, recovery, viral clearance, and peer reviewed studies.

	Improvement	Studies	Patients	Authors
All studies	26% [-14-52%]	3	1,450	37
Peer-reviewed studies	9% [-8-24%]	2	1,422	24
Randomized Controlled Trials	26% [-14-52%]	3	1,450	37
Recovery	10% [-3-22%]	2	1,376	24
Viral	38% [27-47%] ****	3	1,417	37

Table 1. Random effects meta-analysis for all studies, for Randomized Controlled Trials, for peer-reviewed studies, and for specific outcomes. Results show the percentage improvement with treatment and the 95% confidence interval.
**** $p < 0.0001$.


3 ensitrelvir COVID-19 studies

	Improvement, RR [CI]	Treatment	Control
Mukae (DB RCT)	45% 0.55 [0.37-0.81] viral load	14 (n)	14 (n)
Mukae (DB RCT)	9% 0.91 [0.76-1.08] improv.	116 (n)	111 (n)
Yotsuyan.. (DB RCT)	-1% 1.01 [0.06-16.1] hosp.	1/595	1/600
Early treatment	26% 0.74 [0.48-1.14]	1/725	1/725
All studies	26% 0.74 [0.48-1.14]	1/725	1/725

Tau² = 0.08, I² = 63.0%, p = 0.17

Tau² = 0.08, I² = 63.0%, p = 0.17

Effect extraction pre-specified
(most serious outcome, see appendix)



c19early.org
April 2024


Figure 3. Random effects meta-analysis for all studies. This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.

1 ensitrelvir COVID-19 hospitalization result

	Improvement, RR [CI]	Treatment	Control
Yotsuyan.. (DB RCT)	-1% 1.01 [0.06-16.1] hosp.	1/595	1/600
Early treatment	-1% 1.01 [0.06-16.1]	1/595	1/600
All studies	-1% 1.01 [0.06-16.1]	1/595	1/600

Tau² = 0.00, I² = 0.0%, p = 1.

Tau² = 0.00, I² = 0.0%, p = 1.



c19early.org
April 2024

Figure 4. Random effects meta-analysis for hospitalization.

2 ensitrelvir COVID-19 recovery results

c19early.org
April 2024




Figure 5. Random effects meta-analysis for recovery.

3 ensitrelvir COVID-19 viral clearance results

c19early.org
April 2024




Figure 6. Random effects meta-analysis for viral clearance.

2 ensitrelvir COVID-19 peer reviewed studies

c19early.org
April 2024




Figure 7. Random effects meta-analysis for peer reviewed studies. Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below.

Zeraatkar *et al.* analyze 356 COVID-19 trials, finding no significant evidence that preprint results are inconsistent with peer-reviewed studies. They also show extremely long peer-review delays, with a median of 6 months to journal publication. A six month delay was equivalent to around 1.5 million deaths during the first two years of the pandemic. Authors recommend using preprint evidence, with appropriate checks for potential falsified data, which provides higher certainty much earlier.

Davidson *et al.* also showed no important difference between meta analysis results of preprints and peer-reviewed publications for COVID-19, based on 37 meta analyses including 114 trials.

Randomized Controlled Trials (RCTs)

Currently all studies are RCTs.

Heterogeneity

Heterogeneity in COVID-19 studies arises from many factors including:

Treatment delay. The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours *McLean, Treanor*. Baloxavir studies for influenza also show that treatment delay is critical – *Ikematsu et al.* report an 86% reduction in cases for post-exposure prophylaxis, *Hayden et al.* show a 33 hour reduction in the time to alleviation of symptoms for treatment within 24 hours and a reduction of 13 hours for treatment within 24-48 hours, and *Kumar et al.* report only 2.5 hours improvement for inpatient treatment.

Treatment delay	Result
Post-exposure prophylaxis	86% fewer cases <i>Ikematsu</i>
<24 hours	-33 hours symptoms <i>Hayden</i>
24-48 hours	-13 hours symptoms <i>Hayden</i>
Inpatients	-2.5 hours to improvement <i>Kumar</i>

Table 2. Studies of baloxavir for influenza show that early treatment is more effective.

Figure 8 shows a mixed-effects meta-regression for efficacy as a function of treatment delay in COVID-19 studies from 69 treatments, showing that efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.




Figure 8. Early treatment is more effective. Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 69 treatments.

Patient demographics. Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results, for example as in *López-Medina et al.*

Variants. Efficacy may depend critically on the distribution of SARS-CoV-2 variants encountered by patients. Risk varies significantly across variants *Korves*, for example the Gamma variant shows significantly different characteristics *Faria, Karita, Nonaka, Zavascki*. Different mechanisms of action may be more or less effective depending on variants, for example the degree to which TMPRSS2 contributes to viral entry can differ across variants *Peacock, Willett*.

Regimen. Effectiveness may depend strongly on the dosage and treatment regimen.

Other treatments. The use of other treatments may significantly affect outcomes, including supplements, other medications, or other interventions such as prone positioning. Treatments may be synergistic *Alsaïdi, Andreani, De Forni, Fiaschi, Jeffreys, Jitobaom, Jitobaom (B), Ostrov, Said, Thairu, Wan*, therefore efficacy may depend strongly on combined treatments.

Medication quality. The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. *Williams et al.* analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. *Xu et al.* analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer.

Effect measured. Across all studies there is a strong association between different outcomes, for example improved recovery is strongly associated with lower mortality. However, efficacy may differ depending on the effect measured, for example a treatment may be more effective against secondary complications and have minimal effect on viral clearance.

Meta analysis. The distribution of studies will alter the outcome of a meta analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though early treatment is very effective. All meta analyses combine heterogeneous studies, varying in population, variants, and potentially all factors above, and therefore may obscure efficacy by including studies where treatment is less effective. Generally, we expect the estimated effect size from meta analysis to be less than that for the optimal case. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations. While we present results for all studies, we also present treatment time and individual outcome analyses, which may be more informative for specific use cases.

Pooled Effects

Combining studies is required. For COVID-19, delay in clinical results translates into additional death and morbidity, as well as additional economic and societal damage. Combining the results of studies reporting different outcomes is required. There may be no mortality in a trial with low-risk patients, however a reduction in severity or improved viral clearance may translate into lower mortality in a high-risk population. Different studies may report lower severity, improved recovery, and lower mortality, and the significance may be very high when combining the results. "*The studies reported different outcomes*" is not a good reason for disregarding results.

Specific outcome and pooled analyses. We present both specific outcome and pooled analyses. In order to combine the results of studies reporting different outcomes we use the most serious outcome reported in each study, based on the thesis that improvement in the most serious outcome provides comparable measures of efficacy for a treatment. A critical advantage of this approach is simplicity and transparency. There are many other ways to combine evidence for different outcomes, along with additional evidence such as dose-response relationships, however these increase complexity.

Using more information. Another way to view pooled analysis is that we are using more of the available information. Logically we should, and do, use additional information. For example dose-response and treatment delay-response relationships provide significant additional evidence of efficacy that is considered when reviewing the evidence for a treatment.

Ethical and practical issues limit high-risk trials. Trials with high-risk patients may be restricted due to ethics for treatments that are known or expected to be effective, and they increase difficulty for recruiting. Using less severe outcomes as a proxy for more serious outcomes allows faster collection of evidence.

Improvement across outcomes. For many COVID-19 treatments, a reduction in mortality logically follows from a reduction in hospitalization, which follows from a reduction in symptomatic cases, which follows from a reduction in PCR positivity. We can directly test this for COVID-19.

Validating pooled outcome analysis for COVID-19. Analysis of the the association between different outcomes across studies from all 69 treatments we cover confirms the validity of pooled outcome analysis for COVID-19. Figure 9 shows that lower hospitalization is very strongly associated with lower mortality ($p < 0.00000000001$). Similarly, Figure 10 shows that improved recovery is very strongly associated with lower mortality ($p < 0.00000000001$). Considering the extremes, *Singh et al.* show an association between viral clearance and hospitalization or death, with $p = 0.003$ after excluding one large outlier from a mutagenic treatment, and based on 44 RCTs including 52,384 patients. Figure 11 shows that improved viral clearance is strongly associated with fewer serious outcomes. The association is very similar to *Singh et al.*, with higher confidence due to the larger number of studies. As with *Singh et al.*, the confidence increases when excluding the outlier treatment, from $p = 0.0000045$ to $p = 0.000000067$.




Figure 9. Lower hospitalization is associated with lower mortality, supporting pooled outcome analysis.




Figure 10. Improved recovery is associated with lower mortality, supporting pooled outcome analysis.




Figure 9. Improved viral clearance is associated with fewer serious outcomes, supporting pooled outcome analysis.

Pooled outcomes identify efficacy 4 months faster (6 months for RCTs). Currently, 44 of the treatments we analyze show statistically significant efficacy or harm, defined as $\geq 10\%$ decreased risk or $>0\%$ increased risk from ≥ 3 studies. 85% of these have been confirmed with one or more specific outcomes, with a mean delay of 3.7 months. When restricting to RCTs only, 54% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 5.8 months. Figure 12 shows when treatments were found effective during the pandemic. Pooled outcomes often resulted in earlier detection of efficacy.

Time when COVID-19 studies showed efficacy

c19early.org
April 2024




Figure 12. The time when studies showed that treatments were effective, defined as statistically significant improvement of $\geq 10\%$ from ≥ 3 studies. Pooled results typically show efficacy earlier than specific outcome results. Results from all studies often shows efficacy much earlier than when restricting to RCTs. Results reflect conditions as used in trials to date, these depend on the population treated, treatment delay, and treatment regimen.

Limitations. Pooled analysis could hide efficacy, for example a treatment that is beneficial for late stage patients but has no effect on viral clearance may show no efficacy if most studies only examine viral clearance. In practice, it is rare for a non-antiviral treatment to report viral clearance and to not report clinical outcomes; and in practice other sources of heterogeneity such as difference in treatment delay is more likely to hide efficacy.

Summary. Analysis validates the use of pooled effects and shows significantly faster detection of efficacy on average. However, as with all meta analyses, it is important to review the different studies included. We also present individual outcome analyses, which may be more informative for specific use cases.

Discussion

Publication bias. Publishing is often biased towards positive results. Trials with patented drugs may have a financial conflict of interest that results in positive studies being more likely to be published, or bias towards more positive results. For example with molnupiravir, trials with negative results remain unpublished to date (CTRI/2021/05/033864 and CTRI/2021/08/0354242). For ensitrelvir, there is currently not enough data to evaluate publication bias with high confidence.

Limitations. Summary statistics from meta analysis necessarily lose information. As with all meta analyses, studies are heterogeneous, with differences in treatment delay, treatment regimen, patient demographics, variants, conflicts of interest, standard of care, and other factors. We provide analyses for specific outcomes and by treatment delay, and we aim to identify key characteristics in the forest plots and summaries. Results should be viewed in the context of study characteristics.

Some analyses classify treatment based on early or late administration, as done here, while others distinguish between mild, moderate, and severe cases. Viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.

Details of treatment delay per patient is often not available. For example, a study may treat 90% of patients relatively early, but the events driving the outcome may come from 10% of patients treated very late. Our 5 day cutoff for early treatment may be too conservative, 5 days may be too late in many cases.

Comparison across treatments is confounded by differences in the studies performed, for example dose, variants, and conflicts of interest. Trials with conflicts of interest may use designs better suited to the preferred outcome.

In some cases, the most serious outcome has very few events, resulting in lower confidence results being used in pooled analysis, however the method is simpler and more transparent. This is less critical as the number of studies increases. Restriction to outcomes with sufficient power may be beneficial in pooled analysis and improve accuracy when there are few studies, however we maintain our pre-specified method to avoid any retrospective changes.

Studies show that combinations of treatments can be highly synergistic and may result in many times greater efficacy than individual treatments alone *Alsaïdi, Andreani, De Forni, Fiaschi, Jeffreys, Jitobaom, Jitobaom (B), Ostrov, Said, Thairu, Wan*. Therefore standard of care may be critical and benefits may diminish or disappear if standard of care does not include certain treatments.

This real-time analysis is constantly updated based on submissions. Accuracy benefits from widespread review and submission of updates and corrections from reviewers. Less popular treatments may receive fewer reviews.

No treatment or intervention is 100% available and effective for all current and future variants. Efficacy may vary significantly with different variants and within different populations. All treatments have potential side effects. Propensity to experience side effects may be predicted in advance by qualified physicians. We do not provide medical advice. Before taking any medication, consult a qualified physician who can compare all options, provide personalized advice, and provide details of risks and benefits based on individual medical history and situations.

Reviews. *Bischof et al.* present a review covering ensitrelvir for COVID-19.

Perspective

Results compared with other treatments. SARS-CoV-2 infection and replication involves a complex interplay of 50+ host and viral proteins and other factors *Lui, Lv, Malone, Murigneux, Niarakis*, providing many therapeutic targets. Over 7,000 compounds have been predicted to reduce COVID-19 risk *c19early.org*, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications. Figure 13 shows an overview of the results for ensitrelvir in the context of multiple COVID-19 treatments, and Figure 14 shows a plot of efficacy vs. cost for COVID-19 treatments.

Efficacy in COVID-19 studies (pooled effects)

c19early.org
April 2024




Figure 13. Scatter plot showing results within the context of multiple COVID-19 treatments. Diamonds shows the results of random effects meta-analysis. 0.6% of 7,400 proposed treatments show efficacy c19early.org (B).

Efficacy vs. cost for COVID-19 treatments

c19early.org
April 2024




Figure 14. Efficacy vs. cost for COVID-19 treatments.


Conclusion

Statistically significant lower risk is seen for viral clearance. 3 studies from 2 independent teams (all from the same country) show statistically significant improvements. Meta analysis using the most serious outcome reported shows 26% [-14-52%] lower risk, without reaching statistical significance. Results are worse for peer-reviewed studies. Currently all studies are RCTs.

Currently there is limited data, with only 1 control event for the most serious outcome in trials to date. Studies to date are from only 2 different groups.

Study Notes


Mukae



Mukae: RCT 428 COVID-19 patients in Japan showing faster viral clearance and improved recovery with ensitrelvir.

Mukae

Ensitrelvir Mukae et al. EARLY TREATMENT DB RCT




Is early treatment with ensitrelvir beneficial for COVID-19?


Double-blind RCT 69 patients in Japan (September 2021 - January 2022)

Improved viral clearance with ensitrelvir ($p=0.0025$)

c19early.org Mukae et al., medRxiv, May 2022



Mukae (B): RCT 69 patients in in Japan, showing faster viral clearance with ensitrelvir. 5-day ensitrelvir (375mg on day 1 followed by 125 mg daily or 750mg on day 1 followed by 250mg daily).



Yotsuyanagi: RCT 1,821 COVID-19 outpatients in Japan, Vietnam, and South Korea, showing improved viral clearance and improved recovery (significant for patients treated within 3 days of onset) with ensitrelvir. Only 2 hospitalizations were reported, with no deaths.

Appendix 1. Methods and Data

We perform ongoing searches of PubMed, medRxiv, Europe PMC, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.org. Search terms are ensitrelvir and COVID-19 or SARS-CoV-2. Automated searches are performed twice daily, with all matches reviewed for inclusion. All studies regarding the use of ensitrelvir for COVID-19 that report a comparison with a control group are included in the main analysis. This is a living analysis and is updated regularly.

We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome specific analyses. For example, if effects for mortality and cases are both reported, the effect for mortality is used, this may be different to the effect that a study focused on. If symptomatic results are reported at multiple times, we used the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days have preference. Mortality alone is preferred over combined outcomes. Outcomes with zero events in both arms are not used, the next most serious outcome with one or more events is used. For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcomes are considered more important than viral test status. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available. After most or all patients have recovered there is little or no room for an effective treatment to do better, however faster recovery is valuable. If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low SpO₂ is more important than cough. When results provide an odds ratio, we compute the

relative risk when possible, or convert to a relative risk according to *Zhang*. Reported confidence intervals and *p*-values were used when available, using adjusted values when provided. If multiple types of adjustments are reported propensity score matching and multivariable regression has preference over propensity score matching or weighting, which has preference over multivariable regression. Adjusted results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported *p*-values and confidence intervals followed *Altman, Altman (B)*, and Fisher's exact test was used to calculate *p*-values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1 *Sweeting*. Results are expressed with RR < 1.0 favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.12.2) with *scipy* (1.12.0), *pythonmeta* (1.26), *numpy* (1.26.4), *statsmodels* (0.14.1), and *plotly* (5.20.0).

Forest plots are computed using *PythonMeta* *Deng* with the DerSimonian and Laird random effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Results are presented with 95% confidence intervals. Heterogeneity among studies was assessed using the I^2 statistic. Mixed-effects meta-regression results are computed with R (4.1.2) using the *metafor* (3.0-2) and *rms* (6.2-0) packages, and using the most serious sufficiently powered outcome. For all statistical tests, a *p*-value less than 0.05 was considered statistically significant. *Grobid* 0.8.0 is used to parse PDF documents.

We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients). We note that a shorter time may be preferable. Antivirals are typically only considered effective when used within a shorter timeframe, for example 0-36 or 0-48 hours for oseltamivir, with longer delays not being effective *McLean, Treanor*.

We received no funding, this research is done in our spare time. We have no affiliations with any pharmaceutical companies or political parties.

A summary of study results is below. Please submit updates and corrections at <https://c19early.org/enmeta.html>.

Early treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

<p><i>Mukae</i>, 12/7/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Japan, peer-reviewed, 11 authors, study period 2 January, 2022 - 9 February, 2022, trial jRCT2031210350.</p>	<p>relative improvement in symptom score, 9.2% better, RR 0.91, $p = 0.28$, treatment mean 5.42 (± 3.7) $n=116$, control mean 4.92 (± 3.25) $n=111$, 250mg, Table 2.</p>
	<p>relative improvement in symptom score, 17.3% better, RR 0.83, $p = 0.04$, treatment mean 5.95 (± 4.02) $n=114$, control mean 4.92 (± 3.25) $n=111$, 125mg, Table 2.</p>
	<p>time to viral-, 32.4% lower, relative time 0.68, $p < 0.001$, treatment 113, control 108, relative time to first negative viral titer, 250mg, Figure 3.</p>
	<p>time to viral-, 44.2% lower, relative time 0.56, $p < 0.001$, treatment 113, control 108, relative time to first negative viral titer, 125mg, Figure 3.</p>

Mukae (B), 5/17/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Japan, preprint, 13 authors, study period 28 September, 2021 - 1 January, 2022, trial jRCT2031210350.

relative change in viral titer, 45.2% better, RR 0.55, $p = 0.002$, treatment mean 2.81 (± 1.21) $n=14$, control mean 1.54 (± 0.74) $n=14$, day 4, 250mg, primary outcome.

relative change in viral titer, 36.4% better, RR 0.64, $p = 0.048$, treatment mean 2.42 (± 1.42) $n=15$, control mean 1.54 (± 0.74) $n=14$, day 4, 125mg, primary outcome.

time to viral-, 44.8% lower, relative time 0.55, $p = 0.02$, treatment 15, control 14, 125mg.

time to viral-, 43.6% lower, relative time 0.56, $p = 0.02$, treatment 13, control 14, 250mg.

risk of no viral clearance, 54.2% lower, RR 0.46, $p = 0.59$, treatment 1 of 12 (8.3%), control 2 of 11 (18.2%), NNT 10, day 14, 250mg, Figure S1.

risk of no viral clearance, 10.0% higher, RR 1.10, $p = 1.00$, treatment 3 of 15 (20.0%), control 2 of 11 (18.2%), day 14, 125mg, Figure S1.

risk of no viral clearance, 80.0% lower, RR 0.20, $p = 0.48$, treatment 0 of 13 (0.0%), control 2 of 13 (15.4%), NNT 6.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 9, 250mg, Figure S1.

risk of no viral clearance, 53.6% lower, RR 0.46, $p = 0.60$, treatment 1 of 14 (7.1%), control 2 of 13 (15.4%), NNT 12, day 9, 125mg, Figure S1.

risk of no viral clearance, 53.6% lower, RR 0.46, $p = 0.38$, treatment 2 of 14 (14.3%), control 4 of 13 (30.8%), NNT 6.1, day 6, 250mg, Figure S1.

risk of no viral clearance, 89.6% lower, RR 0.10, $p = 0.03$, treatment 0 of 15 (0.0%), control 4 of 13 (30.8%), NNT 3.2, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 6, 125mg, Figure S1.

risk of no viral clearance, 80.0% lower, RR 0.20, $p = 0.006$, treatment 2 of 14 (14.3%), control 10 of 14 (71.4%), NNT 1.8, day 4, 250mg, Figure S1.

risk of no viral clearance, 62.7% lower, RR 0.37, $p = 0.03$, treatment 4 of 15 (26.7%), control 10 of 14 (71.4%), NNT 2.2, day 4, 125mg, Figure S1.

risk of no viral clearance, 9.1% lower, RR 0.91, $p = 1.00$, treatment 10 of 14 (71.4%), control 11 of 14 (78.6%), NNT 14, day 2, 250mg, Figure S1.

risk of no viral clearance, 10.3% higher, RR 1.10, $p = 0.65$, treatment 13 of 15 (86.7%), control 11 of 14 (78.6%), day 2,

	125mg, Figure S1.
<p><i>Yotsuyanagi</i>, 7/13/2023, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, mean age 35.7, 13 authors, study period 10 February, 2022 - 10 July, 2022, trial jRCT2031210350 (SCORPIO-SR).</p>	risk of hospitalization, 0.8% higher, RR 1.01, $p = 1.00$, treatment 1 of 595 (0.2%), control 1 of 600 (0.2%), 250mg.
	risk of hospitalization, 66.7% lower, RR 0.33, $p = 0.50$, treatment 0 of 603 (0.0%), control 1 of 600 (0.2%), NNT 600, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), 125mg.
	recovery time, 11.4% lower, relative time 0.89, $p = 0.30$, treatment 577, control 572, 14 symptoms, randomized within 120 hours, 250mg.
	recovery time, 10.1% lower, relative time 0.90, $p = 0.46$, treatment 582, control 572, 14 symptoms, randomized within 120 hours, 125mg.
	recovery time, 17.9% lower, relative time 0.82, $p = 0.05$, treatment 330, control 321, 14 symptoms, randomized within 72 hours, 250mg.
	recovery time, 19.0% lower, relative time 0.81, $p = 0.03$, treatment 336, control 321, 14 symptoms, randomized within 72 hours, 125mg.
	recovery time, 13.3% lower, relative time 0.87, $p = 0.35$, treatment 577, control 572, 12 symptoms, randomized within 120 hours, 250mg.
	recovery time, 9.7% lower, relative time 0.90, $p = 0.76$, treatment 582, control 572, 12 symptoms, randomized within 120 hours, 125mg.
	recovery time, 13.3% lower, relative time 0.87, $p = 0.08$, treatment 330, control 321, 12 symptoms, randomized within 72 hours, 250mg.
	recovery time, 15.9% lower, relative time 0.84, $p = 0.07$, treatment 336, control 321, 12 symptoms, randomized within 72 hours, 125mg.
	relative change in viral load, 48.8% better, RR 0.51, $p < 0.001$, treatment 579, control 589, randomized within 120 hours, 250mg.
	relative change in viral load, 48.8% better, RR 0.51, $p < 0.001$, treatment 592, control 589, randomized within 120 hours, 125mg.
	relative change in viral load, 59.4% better, RR 0.41, $p < 0.001$, treatment 330, control 321, randomized within 72 hours, 250mg.
relative change in viral load, 59.3% better, RR 0.41, $p < 0.001$, treatment 336, control 321, randomized within 72 hours, 125mg.	

Supplementary Data

Supplementary Data

Footnotes

- a. Viral infection and replication involves attachment, entry, uncoating and release, genome replication and transcription, translation and protein processing, assembly and budding, and release. Each step can be disrupted by therapeutics.
- b. VeroE6/TMPRSS2 is a Vero E6 cell line engineered to express the human serine protease TMPRSS2, enabling SARS-CoV-2 S protein priming and entry.
- c. HEK293T/ACE2-TMPRSS2 is a human embryonic kidney cell line engineered to express human ACE2 and TMPRSS2, making it highly susceptible to SARS-CoV-2 infection.
- d. MucilAir cells are primary human nasal epithelial cells that mimic the structure and physiology of the human airway epithelium.
- e. A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.
- f. A small rodent model used in SARS-CoV-2 research that replicates key aspects of human infection including efficient replication in the upper and lower respiratory tract.
- g. The original SARS-CoV-2 strain that emerged in Wuhan, China in late 2019. Also referred to as wild-type.
- h. A variant of concern first identified in India in late 2020, delta (B.1.617.2) transmitted more efficiently than previous variants. It contains spike mutations including L452R which increases binding to the ACE2 receptor.
- i. A highly transmissible variant of concern first detected in South Africa in late 2021. Omicron possesses many spike mutations which confer partial immune evasion, including deletions near the furin cleavage site.

References

1. **Alsaïdi** et al., *Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model*, Marine Drugs, doi:10.3390/md19080418.
2. **Altman**, D., *How to obtain the P value from a confidence interval*, BMJ, doi:10.1136/bmj.d2304.
3. **Altman (B)** et al., *How to obtain the confidence interval from a P value*, BMJ, doi:10.1136/bmj.d2090.
4. **Andreani** et al., *In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect*, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.
5. **Bischof**, E., *Mitigating COVID-19 Mortality and Morbidity in China's Aging Population: A Focus on Available Medications and Future Developments*, Aging and disease, doi:10.14336/AD.2023.0318.
6. **c19early.org**, c19early.org/treatments.html.
7. **c19early.org (B)**, c19early.org/timeline.html.
8. **Davidson** et al., *No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study*, Journal of Clinical Epidemiology, doi:10.1016/j.jclinepi.2023.08.011.
9. **De Forni** et al., *Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients*, PLoS ONE, doi:10.1371/journal.pone.0276751.
10. **Deng**, H., *PyMeta, Python module for meta-analysis*, www.pymeta.com/.

11. **Duloquin** et al., *Is COVID-19 Infection a Multiorganic Disease? Focus on Extrapulmonary Involvement of SARS-CoV-2*, Journal of Clinical Medicine, doi:10.3390/jcm13051397.
12. **Eberhardt** et al., *SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels*, Nature Cardiovascular Research, doi:10.1038/s44161-023-00336-5.
13. **Faria** et al., *Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil*, Science, doi:10.1126/science.abh2644.
14. **Fiaschi** et al., *In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants*, Viruses, doi:10.3390/v16020168.
15. **Hampshire** et al., *Cognition and Memory after Covid-19 in a Large Community Sample*, New England Journal of Medicine, doi:10.1056/NEJMoa2311330.
16. **Hayden** et al., *Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents*, New England Journal of Medicine, doi:10.1056/NEJMoa1716197.
17. **Ikematsu** et al., *Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts*, New England Journal of Medicine, doi:10.1056/NEJMoa1915341.
18. **Jeffreys** et al., *Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2*, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542.
19. **Jitobaom** et al., *Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2*, Research Square, doi:10.21203/rs.3.rs-941811/v1.
20. **Jitobaom (B)** et al., *Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations*, BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8.
21. **Karita** et al., *Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection*, medRxiv, doi:10.1101/2021.08.27.21262754.
22. **Korves** et al., *SARS-CoV-2 Genetic Variants and Patient Factors Associated with Hospitalization Risk*, medRxiv, doi:10.1101/2024.03.08.24303818.
23. **Kumar** et al., *Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial*, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00469-2.
24. **Kuroda** et al., *Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo*, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkad027.
25. **López-Medina** et al., *Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial*, JAMA, doi:10.1001/jama.2021.3071.
26. **Lui** et al., *Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling*, Virology, doi:10.1128/mbio.00392-24.
27. **Lv** et al., *Host proviral and antiviral factors for SARS-CoV-2*, Virus Genes, doi:10.1007/s11262-021-01869-2.
28. **Malone** et al., *Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design*, Nature Reviews Molecular Cell Biology, doi:10.1038/s41580-021-00432-z.
29. **McLean** et al., *Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial*, Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100.
30. **Mukae** et al., *Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study*, Clinical Infectious Diseases, doi:10.1093/cid/ciac933.
31. **Mukae (B)** et al., *A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part*, medRxiv, doi:10.1101/2022.05.17.22275027.
32. **Murigneux** et al., *Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly*, Nature Communications, doi:10.1038/s41467-024-44958-0.

33. **Niarakis** et al., *Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches*, *Frontiers in Immunology*, doi:10.3389/fimmu.2023.1282859.
34. **Nobori** et al., *Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2*, *Antiviral Research*, doi:10.1016/j.antiviral.2024.105852.
35. **Nonaka** et al., *SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021*, *International Journal of Infectious Diseases*, doi:10.1016/j.ijid.2021.08.003.
36. **Ostrov** et al., *Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells*, *Pathogens*, doi:10.3390/pathogens10111514.
37. **Peacock** et al., *The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry*, *bioRxiv*, doi:10.1101/2021.12.31.474653.
38. **Said** et al., *The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial*, *Frontiers in Pharmacology*, doi:10.3389/fphar.2022.1011522.
39. **Scardua-Silva** et al., *Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19*, *Scientific Reports*, doi:10.1038/s41598-024-52005-7.
40. **Singh** et al., *The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis*, *Journal of Antimicrobial Chemotherapy*, doi:10.1093/jac/dkac045.
41. **Sweeting** et al., *What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data*, *Statistics in Medicine*, doi:10.1002/sim.1761.
42. **Thairu** et al., *A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality*, *Journal of Pharmaceutical Research International*, doi:10.9734/jpri/2022/n34i44A36328.
43. **Treanor** et al., *Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial*, *JAMA*, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016.
44. **Wan** et al., *Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level*, *Scientific Reports*, doi:10.1038/s41598-024-54722-5.
45. **Willett** et al., *The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism*, *medRxiv*, doi:10.1101/2022.01.03.21268111.
46. **Williams**, T., *Not All Ivermectin Is Created Equal: Comparing The Quality of 11 Different Ivermectin Sources*, *Do Your Own Research*, doyourownresearch.substack.com/p/not-all-ivermectin-is-created-equal.
47. **Xu** et al., *A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate by UHPLC-Q/TOF-MS and LC-SPE-NMR*, *Rapid Communications in Mass Spectrometry*, doi:10.1002/rcm.9358.
48. **Yang** et al., *SARS-CoV-2 infection causes dopaminergic neuron senescence*, *Cell Stem Cell*, doi:10.1016/j.stem.2023.12.012.
49. **Yotsuyanagi** et al., *Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial*, *JAMA Network Open*, doi:10.1001/jamanetworkopen.2023.54991.
50. **Zavascki** et al., *Advanced ventilatory support and mortality in hospitalized patients with COVID-19 caused by Gamma (P.1) variant of concern compared to other lineages: cohort study at a reference center in Brazil*, *Research Square*, doi:10.21203/rs.3.rs-910467/v1.
51. **Zeraatkar** et al., *Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review*, *BMJ Medicine*, doi:10.1136/bmjmed-2022-0003091.
52. **Zhang** et al., *What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes*, *JAMA*, 80:19, 1690, doi:10.1001/jama.280.19.1690.